STEAP2 is an integral membrane protein with six transmembrane domains that functions as a NADPH-dependent metalloreductase, catalyzing the reduction of Fe(3+) chelates and Cu(2+) to Cu(1+) through sequential electron transfer from NADPH to FAD, heme, and finally to metal chelates 1. The protein is predominantly localized to the plasma membrane and is highly expressed in normal prostate tissue, with expression levels more than 10-fold higher than other tissues 1. STEAP2 plays significant roles in cancer biology, particularly in prostate cancer where it promotes aggressive phenotypes including proliferation, migration, and invasion through regulation of matrix metalloproteinases and other metastasis-associated genes 2. The protein induces epithelial-mesenchymal transition via the PI3K/AKT/mTOR signaling pathway in osteosarcoma 3. STEAP2 expression is significantly elevated in prostate cancer compared to benign hyperplasia and correlates with Gleason score, making it a potential biomarker 21. Its restricted tissue distribution and cell surface localization make STEAP2 an attractive therapeutic target, with CAR-T cell therapies like AZD0754 showing promising preclinical results in prostate cancer models 4. Additionally, STEAP2 serves as a potential marker for mesenchymal stem cells in both mice and humans 5.